Internal Medicine, Nephrology · Flagstaff, AZ
NPI
1114950185
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2201 N Vickey St Ste 110
Flagstaff, AZ, 86004
Phone (928) 213-9460
Groups this clinician bills Medicare through
Medicare paid, 2024
$117K
1,257 services
Medicare patients, 2024
441
Average age 74
Drug cost, 2024
$261K
1,158 prescriptions
Company payments, 2025
$614
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew I Gembala was code 99215 (office e&m - established), 618 times for 301 patients. In total Matthew I Gembala billed 1,257 services in 16 codes, and Medicare paid $117K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-10-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 618 | 301 | $124.47 | $77K |
| 99205 Office E&M - New | Office | 77 | 77 | $139.20 | $11K |
| 99233 Hospital E&M - Subsequent | Facility | 75 | 46 | $85.70 | $6,428 |
| 99214 Office E&M - Established | Office | 61 | 59 | $83.59 | $5,099 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 27 | 27 | $11.98 | $324 |
| 90961 ESRD Related Services (not dialysis) | Office | 20 | 13 | $218.88 | $4,378 |
| 90960 ESRD Related Services (not dialysis) | Office | 20 | 16 | $236.45 | $4,729 |
| 99223 Hospital E&M - Initial | Facility | 19 | 19 | $131.80 | $2,504 |
| 90962 ESRD Related Services (not dialysis) | Office | 15 | 13 | $149.82 | $2,247 |
By year: 2022 $125K for 1,301 services; 2023 $104K for 1,073 services; 2024 $117K for 1,257 services.
Medicare prescription drug claims, 2024
In 2024, the drug Matthew I Gembala prescribed most often to Medicare patients was Losartan Potassium, with 103 prescriptions and refills. In total Matthew I Gembala wrote 1,158 Medicare prescriptions that cost $261K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Losartan Potassium Generic | 103 | 264 | 33 | $1,013 |
| Allopurinol Generic | 70 | 173 | 23 | $514 |
| Amlodipine Besylate Generic | 62 | 168 | 24 | $387 |
| Furosemide Generic | 61 | 137 | 21 | $356 |
| Lisinopril Generic | 58 | 146 | 20 | $537 |
| Chlorthalidone Generic | 48 | 119 | 13 | $1,313 |
| Febuxostat Generic | 45 | 105 | 13 | $8,078 |
| Sevelamer Carbonate Generic | 45 | 51 | Under 11 | $4,258 |
| Tamsulosin Hcl Generic | 41 | 103 | 12 | $962 |
| Atorvastatin Calcium Generic | 33 | 75 | Under 11 | $487 |
| Metoprolol Succinate Generic | 30 | 90 | Under 11 | $505 |
| Potassium Chloride Generic | 26 | 66 | 11 | $777 |
| Finasteride Generic | 26 | 76 | Under 11 | $310 |
| Pantoprazole Sodium Generic | 26 | 78 | Under 11 | $152 |
| Rosuvastatin Calcium Generic | 21 | 63 | Under 11 | $310 |
Brand drugs: 132 claims; generic drugs: 1,026 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew I Gembala $614 ($614 in general payments such as food, travel and fees) from 10 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $170.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 8 | $170 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 6 | $163 |
| Akebia Therapeutics Inc AKBA | 4 | $85.9 |
| Amgen Inc. AMGN | 2 | $45.37 |
| Chiesi USA, Inc. | 1 | $33.48 |
| Travere Therapeutics, Inc. TVTX | 1 | $32.24 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $26.28 |
| CorMedix Inc. CRMD | 1 | $23.1 |
| Mallinckrodt Hospital Products Inc. | 1 | $21.4 |
| Novo Nordisk Inc NVO | 1 | $13.93 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.